iECURE Secures Clearance from Australian Therapeutic Goods Administration for its Clinical Trial Approval for the OTC-HOPE Phase 1/2 Study of ECUR-506
December 13, 2023
iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver Diseases
November 30, 2022
Preclinical Data from iECURE’s GTP-506 Demonstrates Potential for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
October 19, 2022
iECURE Appoints George Diaz, M.D., Ph.D., as VP, Therapeutic Area Lead for Urea Cycle Disorders
April 25, 2022
iECURE Partners to Develop Next-Generation Liver-Targeted Lipid Nanoparticles with University of Pennsylvania
December 16, 2021
iECURE Bolsters Senior Management Team with Appointment of David Garrett as Chief Financial Officer
December 06, 2021
iECURE Appoints Brian Di Donato to Board of Directors
September 15, 2021
iECURE Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases
September 9, 2021
https://iecure.com/wp-content/uploads/Science_logo.png
52
280
eallison
/wp-content/uploads/iEcure_logo.png
eallison2025-01-30 17:53:142025-01-30 18:02:36Gene editor may have cured infant of a deadly metabolic disorder
Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago
January 8, 2025
Introducing Fierce Biotech’s 2024 Fierce 15
August 5, 2024
https://iecure.com/wp-content/uploads/philadelphia-logo.svg
0
0
eallison
/wp-content/uploads/iEcure_logo.png
eallison2024-05-29 17:19:002024-05-29 17:46:01University of Pennsylvania gene-editing spinout iEcure hits the FDA trifectaExclusive: Jim Wilson startup gets FDA green light for first test of gene editing in babies
April 4, 2024
34 healthcare and biotech startups that are set to take off in 2022, according to top investors
Dec 20, 2021
https://iecure.com/wp-content/uploads/logo-MedCity.svg
52
280
eallison
/wp-content/uploads/iEcure_logo.png
eallison2021-12-01 19:29:522021-12-29 20:44:37Genetic meds pioneer James Wilson has a new startup, this time in gene editing
Penn gene editing spinout iECURE just raised a $50M Series A
September 10, 2021
https://iecure.com/wp-content/uploads/cen-logo.svg
52
280
eallison
/wp-content/uploads/iEcure_logo.png
eallison2021-12-01 19:26:302021-12-29 21:00:35Jim Wilson launches liver disease gene-editing company iECURE with $50 millioniECURE emerges with $50M to search for ‘holy grail’ and ‘untapped frontier’ of gene editing
September 9, 2021
The Tachi Yamada legacy tree continues to grow with a new gene editing biotech from Jim Wilson
September 9, 2021
https://iecure.com/wp-content/uploads/forbes_logo_white.svg
50
198
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2021-09-09 08:00:322025-01-30 18:04:24This Startup Just Raised $50 Million To Deliver Gene Therapies For Rare DiseasesDecreased rate of hyperammonemiccrises in infants with neonatal-onset OTC deficiency (OTCD) post ECUR-506 administration
Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM)
August 27, 2026
Decreased rate of hyperammonemic crises in infants with neonatal-onset OTC deficiency post ECUR-506 administration: Preliminary update from the OTC-HOPE study
Canadian College of Medical Geneticists (CCMG) & Garrod Association Joint Conference
June 10, 2026
Sustained Clinical Response in First Patient Dosed With ECUR-506 One Year Post Discontinuation of Standard of Care
Society for Inherited Metabolic Disorders (SIMD) 2026 Annual Meeting
May 18, 2026
Decreased rate of hyperammonemic crises in infants with neonatal-onset OTC deficiency post ECUR-506 administration: preliminary update from the OTC-HOPE study
American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
May 13, 2026
Eighteen-Month Clinical Update from the First Patient Dosed in OTC-HOPE
Ureagenesis Meeting 2026
April 22, 2026
OTC-HOPE: The first in vivo, liver directed, AAV-mediated, gene insertion clinical trial in infants with Ornithine Transcarbamylase Deficiency
American Society of Human Genetics (ASHG) Annual Meeting
October 16, 2025
Initial Findings from the First Four Patients Enrolled in OTC-HOPE Clinical Trial: No Hyperammonemic Events in First Participant to Complete 24-week Study
15th International Congress of Inborn Errors of Metabolism (ICIEM)
September 4, 2025
Initial clinical results from OTC-HOPE, the first in vivo, liver directed, AAV-mediated gene insertion study in neonatal OTC deficiency: complete clinical response observed in first male infant to receive ECUR-506 and complete 24-week Phase 1/2 study
2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 13, 2025
A First in Human, Single Arm, Open Label Phase 1/2 Study Evaluating ECUR-506 in Neonatal OTC Deficiency: Initial Observations
2025 ACMG Annual Clinical Genetics Meeting
March 21, 2025